Dan Burrows

Dan Burrows

InvestorPlace Feature Writer

Dan Burrows is a veteran of CBS MoneyWatch, DailyFinance, SmartMoney and Dow Jones MarketWatch, and has written for The Wall Street Journal, Consumer Reports and other publications. He favors value investing and writes about asset prices and macroeconomic trends for the long-term investor. He holds no individual securities.

Recent Articles

4 Alternative Energy Funds That Are Crushing the Market

By Dan Burrows, InvestorPlace Feature Writer

From solar power to Telsa Motors, better fundamentals and stricter regulations are fueling some alternative energy funds to dizzying heights this year.

Morgan Stanley Earnings Should Prop the Stock

By Dan Burrows, InvestorPlace Feature Writer

Anyone holding MS stock is looking at 50% gain this year, and a Morgan Stanley earnings swing back into the black should fuel shares even more.

Regional Bank Stocks – This Rally Hinges on Q3 Results

By Dan Burrows, InvestorPlace Feature Writer

USB, PNC and others need to serve up some beat-and-raise earnings for the big rally in regional bank stocks to continue through year-end.

Buy BP Stock Before It’s Too Late

By Dan Burrows, InvestorPlace Feature Writer

The British oil giant faces billions more in costs stemming from the Deepwater Horizon disaster, but that's more than reflected in BP stock.

Will JPM and WFC Slip on Earnings Reports?

By Dan Burrows, InvestorPlace Feature Writer

Lower profits at JPMorgan (JPM) and softer revenue at Wells Fargo (WFC) could spark buying opportunities in the pair of bank stocks.

First S&P Dividend Aristocrats ETF Debuts

By Dan Burrows, InvestorPlace Feature Writer

A new ProShares ETF tracks the S&P Dividend Aristocrats, an index comprised of companies that have hiked their dividends every year for at least 25 years.

3 Surprising (and Surprisingly Cheap) Hot Growth Stocks

By Dan Burrows, InvestorPlace Feature Writer

When it comes to hot growth stocks, Tesla, Amazon and Netflix get all the ink, but these high-quality names are racking up profits -- and are on sale, too.

Should I Buy GlaxoSmithKline (GSK)? 3 Pros, 3 Cons

By Dan Burrows, InvestorPlace Feature Writer

GlaxoSmithKline is seeking approval for the world's first malaria vaccine, but high debt and low growth mean investors should think twice before buying.

3 Stocks You Need to Sell NOW

By Dan Burrows, InvestorPlace Feature Writer

Recommendations to sell are so rare on Wall Street that when analysts actually dole one out, you have to take notice. Here are three such stocks to sell.

Q3 Earnings Season: It’ll Be Crappy, and Wall Street Won’t Care

By Dan Burrows, InvestorPlace Feature Writer

A record number of Q3 profit warnings means we'll get lots of positive surprises this earnings season. Too bad 'better-than-expected' isn't the same thing as 'good.'

Load More